Cesar Reyes, MD
Obstetrics & Gynecology · Live Oak, TXNPI 1801885959
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 24.9% of the total. Reporting peaked in 2022 at $382 and has fallen 90.4% since, to $37 in 2025.
Across 60 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$291
- Exeltis, USA Inc.$129
- Organon$92
- Millicent US Inc$82
- Mayne Pharma Commercial LLC$71
- Sumitomo Pharma America, Inc.$66
- plus $439 from 17 others
What the payments were for
- Food & beverage$1,171100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $291 |
| Exeltis, USA Inc. | 7 | $129 |
| Organon | 5 | $92 |
| Millicent US Inc | 5 | $82 |
| Mayne Pharma Commercial LLC | 3 | $71 |
| Sumitomo Pharma America, Inc. | 3 | $66 |
| Avion Pharmaceuticals | 3 | $63 |
| Merck | 2 | $38 |
| Aspira Women's Health Inc | 2 | $35 |
| Mylan Pharmaceuticals Inc. | 2 | $33 |
| Shield Therapeutics Inc | 2 | $30 |
| Acessa Health Inc. | 1 | $28 |
| Pfizer | 2 | $26 |
| Medtronic | 1 | $25 |
| Bayer | 1 | $24 |
| Abbott | 1 | $22 |
| Myovant Sciences Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Ascend Therapeutics US, LLC | 1 | $19 |
| Covidien LP | 1 | $18 |
| Agile Therapeutics, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Lupin Inc. | 1 | $11 |
How this compares
$1,171 in reported general payments places this provider in the 55th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 35 | $3,230 |
| YuvafemEstradiol | 19 | $2,691 |
| ValacyclovirValacyclovir Hcl | 11 | $624 |
| Triamcinolone Acetonide | 16 | $137 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Live Oak
- Susan CrockettLive Oak$269K
- Devin GarzaAustin$2M
- Shawn TassoneAustin$1.3M
- Dale StovallDallas$590K
- Karyn-Anne CumberbatchMissouri City$452K
- Robert AsgharianEl Paso$366K
- Catherine HansenWebster$357K
- Lisa JukesBee Cave$270K
- Henry Garza IiiSan Antonio$258K
- Rene LunaMcAllen$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.